![]() ![]() Another five billion doses are the subject of negotiations among these same parties that have yet to be finalized. The Launch and Scale analysis revealed that while it will likely take three to four years to manufacture enough vaccines to cover the world’s population, nearly four billion doses of COVID-19 vaccine candidates are already part of bilateral advance purchasing deals involving mainly high-income countries, vaccine developers and global vaccine manufacturers. While other assessments have warned of potential inequalities in vaccine access, this new analysis is the first to carefully quantify the amount of vaccine doses that are being claimed by country-level agreements and how this could delay access to COVID-19 protection across large regions - including sub-Saharan Africa - until almost the middle of the decade. Urli Hodges added, “Countries are hedging bets by making direct deals while also participating in multilateral platforms, which drives inequality and threatens to prolong a global pandemic.” “An ambitious effort to create a global system of vaccine equity is being undermined as a handful of countries - including those who made a commitment to equality - secure as many doses as they possibly can,” said Elina Urli Hodges, MSPH, who leads the Center’s Launch and Scale Speedometer, an initiative that identifies impediments to delivering health innovations to low-income countries. The analysis, released by the Duke Global Health Innovation Center, shows that many of these countries will be able to vaccinate their entire populations - and some will be able to do so many times over - before billions of people are vaccinated in low-income countries. The doctor providing treatment may conduct an individual assessment of the need for vaccination.A new global assessment of purchasing agreements for COVID-19 vaccines reveals that high-income countries, as well as a few middle-income countries flush with manufacturing capacity, have already purchased nearly 3.8 billion doses, with options for another five billion. Staff in health and social care who work closely with patients and care recipients with an increased risk of severe flu, for example in special housing for older people (SÄBO) and in home care services.Household contacts, both children and adults, of people with severely compromised immune systems.Children between 6 months and 17 years of age with diseases, diagnoses and conditions as described in the above list for adults. ![]() Vaccination against flu is recommended for the following groups: Such other reasons may include psychiatric illness or dementia, as well as alcohol or drug abuse. In addition to these defined risk groups, are people who need help with activities in daily life from home care services or similar, as well as people with significantly impaired health for reasons other than the diagnoses above. Other groups that can be particularly considered for COVID-19 vaccination, Conditions that severely weaken the immune system as a result of illness or treatment, including Down’s Syndrome.extreme obesity, neuromuscular disorders or multiple disabilities). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |